Shiseido Company, Limited
Notice Regarding Recording of Equity Method Investment Valuation Loss in the 2025 December Term Individual Financial Summary
In the individual financial summary for the fiscal year ending December 2025, Shiseido recorded an equity method investment valuation loss of 180.3 billion yen as an extraordinary loss, with no impact on the consolidated financial results.
Key Figures
- Equity Method Investment Valuation Loss: 180.3 billion yen (extraordinary loss recorded)
- Impact on Consolidated Financial Results: None
- Announcement Date: 2026-02-10
AI要約
Regarding the Recording of Equity Method Investment Valuation Loss
Shiseido Company, Limited recognized a decline in the fair value of shares of Shiseido Americas Corp. in its individual financial statements for the fiscal year ending December 2025 and recorded an equity method investment valuation loss of 180.3 billion yen as an extraordinary loss based on the Japanese GAAP "Accounting Standard for Financial Instruments." This relates to the revision of full-year earnings guidance and the announcement regarding goodwill impairment losses for the Americas business disclosed on November 10, 2025.
Impact on Consolidated Financial Results and Future Outlook
This equity method investment valuation loss is recorded only in the individual financial statements, and it is clearly stated that there will be no impact on consolidated full-year financial results or future outlook for 2025. Therefore, no changes are indicated in the performance evaluation on a consolidated basis.
